Comparing the associations between host and tumor factors with survival outcomes with anti-PD-1 immunotherapy in metastatic melanoma.

Koczka, Kim; Rigo, Rodrigo; Batuyong, Eugene; Cook, Sara; Asad, Mohammad; Vallerand, Isabelle; Suo, Aleksi; Wang, Edwin; Cheng, Tina

Koczka, Kim; Rigo, Rodrigo; Batuyong, Eugene; Cook, Sara; Asad, Mohammad; Vallerand, Isabelle; Suo, Aleksi; Wang, Edwin; Cheng, Tina.

Afiliación

Koczka K; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
Rigo R; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
Batuyong E; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cook S; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Asad M; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Vallerand I; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Suo A; Department of Oncology, British Columbia Cancer Agency, Abbotsford, British Columbia, Canada.
Wang E; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cheng T; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

Cancer Med ; 12(3): 2427-2439, 2023 02.

Article en En | MEDLINE | ID: mdl-35924450

Asunto(s)

Melanoma; Humanos; Resultado del Tratamiento; Estudios Retrospectivos; Melanoma/patología; Pronóstico; Inmunoterapia; Alberta

Palabras clave

melanoma; prognostic; survival and immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Melanoma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google